Differential impact of conventional oral or transdermal hormone replacement therapy or tibolone on body composition in postmenopausal women

OBJECTIVE To compare the effects on body composition and body weight of tibolone vs two different sequential oral or transdermal oestrogen‐progestogen hormone replacement therapies versus no therapy. PATIENTS AND METHODS One hundred postmenopausal women were assigned to a control group (n = 26), or...

Full description

Saved in:
Bibliographic Details
Published in:Clinical endocrinology (Oxford) 1998-06, Vol.48 (6), p.691-699
Main Authors: Hänggi, Willy, Lippuner, Kurt, Jaeger, Philippe, Birkhäuser, Martin H., Horber, Fritz F.
Format: Article
Language:English
Subjects:
Absorptiometry, Photon
Administration, Cutaneous
Administration, Oral
Biological and medical sciences
Body Composition - drug effects
Dydrogesterone - administration & dosage
Dydrogesterone - therapeutic use
Estradiol - administration & dosage
Estradiol - therapeutic use
Estrogen Replacement Therapy
Female
Genital system. Reproduction
Humans
Medical sciences
Middle Aged
Norpregnenes - therapeutic use
Pharmacology. Drug treatments
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4571-f923b582948892141027026d73666e3f83d2e8c40a3603877feb533da087a8f03
cites cdi_FETCH-LOGICAL-c4571-f923b582948892141027026d73666e3f83d2e8c40a3603877feb533da087a8f03
container_end_page 699
container_issue 6
container_start_page 691
container_title Clinical endocrinology (Oxford)
container_volume 48
creator Hänggi, Willy
Lippuner, Kurt
Jaeger, Philippe
Birkhäuser, Martin H.
Horber, Fritz F.
description OBJECTIVE To compare the effects on body composition and body weight of tibolone vs two different sequential oral or transdermal oestrogen‐progestogen hormone replacement therapies versus no therapy. PATIENTS AND METHODS One hundred postmenopausal women were assigned to a control group (n = 26), or randomized to 1) tibolone (TIB) 2.5 mg/day (n = 28), 2) oral oestradiol 2 mg/day (PO) plus sequential dydrogesterone 10 mg/day for 14 of 28 days per cycle (n = 26), or 3) transdermal oestradiol patch (TTS) releasing 50 μg/day plus oral sequential dydrogesterone 10 mg/day for 14 of 28 days per cycle (n = 20). Body composition was measured at the baseline and every 6 months for 2 years by DXA (Hologic QDR 1000 W). RESULTS Total body fat mass increased (P 
doi_str_mv 10.1046/j.1365-2265.1998.00481.x
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73873946</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>30738300</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4571-f923b582948892141027026d73666e3f83d2e8c40a3603877feb533da087a8f03</originalsourceid><addsrcrecordid>eNqNUcuO0zAUtRBoKAOfgGQhxC7Bj_glsWHK0EEaDRIPsbScxNa4JHGwE6b9Bn4ap626YMXG9r3nYd17AIAYlRhV_O22xJSzghDOSqyULBGqJC53j8DqDDwGK0QRKhDn1VPwLKUtQohJJC7AhRKYMsZX4M8H75yNdpi86aDvR9NMMDjYhOH30gxDbod4OOAUzZBaG_tc3ofYh8HCaMfONLbPZDjd22jG_YHq69AteBhgHdp9NuzHkPziCP0A83vKmjCaOWW3h5CL5-CJM12yL073Jfj-8frb-qa4_bz5tH5_WzQVE7hwitCaSaIqKRXBFUZEIMJbQTnnljpJW2JlUyFDOaJSCGdrRmlrkBRGOkQvwZuj7xjDr9mmSfc-NbbrzGDDnLTIIqoqnomv_iFuwxzzRpLGSuZNYi4ySR5JTQwpRev0GH1v4l5jpJew9FYvmeglE72EpQ9h6V2Wvjz5z3Vv27PwlE7GX59wkxrTubz-xqczjRDFJFvmeXekPfjO7v_7e72-vsuPLC-Ocp8muzvLTfyp83iC6R93G803X66k-Hqlb-hfce_AKA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>198807167</pqid></control><display><type>article</type><title>Differential impact of conventional oral or transdermal hormone replacement therapy or tibolone on body composition in postmenopausal women</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Hänggi, Willy ; Lippuner, Kurt ; Jaeger, Philippe ; Birkhäuser, Martin H. ; Horber, Fritz F.</creator><creatorcontrib>Hänggi, Willy ; Lippuner, Kurt ; Jaeger, Philippe ; Birkhäuser, Martin H. ; Horber, Fritz F.</creatorcontrib><description>OBJECTIVE To compare the effects on body composition and body weight of tibolone vs two different sequential oral or transdermal oestrogen‐progestogen hormone replacement therapies versus no therapy. PATIENTS AND METHODS One hundred postmenopausal women were assigned to a control group (n = 26), or randomized to 1) tibolone (TIB) 2.5 mg/day (n = 28), 2) oral oestradiol 2 mg/day (PO) plus sequential dydrogesterone 10 mg/day for 14 of 28 days per cycle (n = 26), or 3) transdermal oestradiol patch (TTS) releasing 50 μg/day plus oral sequential dydrogesterone 10 mg/day for 14 of 28 days per cycle (n = 20). Body composition was measured at the baseline and every 6 months for 2 years by DXA (Hologic QDR 1000 W). RESULTS Total body fat mass increased (P &lt; 0.05) in controls (+ 3.6 ± 1.5%) and in TTS treated (+ 4.7 ± 2.2%), but not in PO (−1.2 ± 2.4%) and TIB (−1.6 ± 2.2%) treated subjects. This increase in total fat mass in controls and TTS treated women was mostly due to an increase in fat mass of the trunk (P &lt; 0.05), but not legs. As a result, a redistribution of body fat to the trunk occurred in controls, TTS and TIB, but not in PO treated women (P &lt; 0.05). Total lean body mass decreased (P &lt; 0.02) in controls (−1.7 ± 0.7%) and PO (−1.4 ± 0.6%), but not in TTS (+ 0.3 ± 0.8%) and TIB (+ 0.4 ± 0.5%) treated subjects. CONCLUSIONS The menopause is associated with an increase in total body fat and a decline in lean body mass. Oral oestradiol/dydrogesterone and tibolone prevent total body fat changes, whereas transdermal oestradiol/oral dydrogesterone and tibolone prevent the lean mass changes. Furthermore, oral oestradiol/dydrogesterone prevents the shift to a cen_tral, android fat distribution.</description><identifier>ISSN: 0300-0664</identifier><identifier>EISSN: 1365-2265</identifier><identifier>DOI: 10.1046/j.1365-2265.1998.00481.x</identifier><identifier>PMID: 9713556</identifier><identifier>CODEN: CLECAP</identifier><language>eng</language><publisher>Oxford BSL: Blackwell Science Ltd, UK</publisher><subject>Absorptiometry, Photon ; Administration, Cutaneous ; Administration, Oral ; Biological and medical sciences ; Body Composition - drug effects ; Dydrogesterone - administration &amp; dosage ; Dydrogesterone - therapeutic use ; Estradiol - administration &amp; dosage ; Estradiol - therapeutic use ; Estrogen Replacement Therapy ; Female ; Genital system. Reproduction ; Humans ; Medical sciences ; Middle Aged ; Norpregnenes - therapeutic use ; Pharmacology. Drug treatments</subject><ispartof>Clinical endocrinology (Oxford), 1998-06, Vol.48 (6), p.691-699</ispartof><rights>Blackwell Science Ltd, Oxford</rights><rights>1998 INIST-CNRS</rights><rights>Copyright Blackwell Scientific Publications Ltd. Jun 1998</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4571-f923b582948892141027026d73666e3f83d2e8c40a3603877feb533da087a8f03</citedby><cites>FETCH-LOGICAL-c4571-f923b582948892141027026d73666e3f83d2e8c40a3603877feb533da087a8f03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2295850$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9713556$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hänggi, Willy</creatorcontrib><creatorcontrib>Lippuner, Kurt</creatorcontrib><creatorcontrib>Jaeger, Philippe</creatorcontrib><creatorcontrib>Birkhäuser, Martin H.</creatorcontrib><creatorcontrib>Horber, Fritz F.</creatorcontrib><title>Differential impact of conventional oral or transdermal hormone replacement therapy or tibolone on body composition in postmenopausal women</title><title>Clinical endocrinology (Oxford)</title><addtitle>Clinical Endocrinology</addtitle><description>OBJECTIVE To compare the effects on body composition and body weight of tibolone vs two different sequential oral or transdermal oestrogen‐progestogen hormone replacement therapies versus no therapy. PATIENTS AND METHODS One hundred postmenopausal women were assigned to a control group (n = 26), or randomized to 1) tibolone (TIB) 2.5 mg/day (n = 28), 2) oral oestradiol 2 mg/day (PO) plus sequential dydrogesterone 10 mg/day for 14 of 28 days per cycle (n = 26), or 3) transdermal oestradiol patch (TTS) releasing 50 μg/day plus oral sequential dydrogesterone 10 mg/day for 14 of 28 days per cycle (n = 20). Body composition was measured at the baseline and every 6 months for 2 years by DXA (Hologic QDR 1000 W). RESULTS Total body fat mass increased (P &lt; 0.05) in controls (+ 3.6 ± 1.5%) and in TTS treated (+ 4.7 ± 2.2%), but not in PO (−1.2 ± 2.4%) and TIB (−1.6 ± 2.2%) treated subjects. This increase in total fat mass in controls and TTS treated women was mostly due to an increase in fat mass of the trunk (P &lt; 0.05), but not legs. As a result, a redistribution of body fat to the trunk occurred in controls, TTS and TIB, but not in PO treated women (P &lt; 0.05). Total lean body mass decreased (P &lt; 0.02) in controls (−1.7 ± 0.7%) and PO (−1.4 ± 0.6%), but not in TTS (+ 0.3 ± 0.8%) and TIB (+ 0.4 ± 0.5%) treated subjects. CONCLUSIONS The menopause is associated with an increase in total body fat and a decline in lean body mass. Oral oestradiol/dydrogesterone and tibolone prevent total body fat changes, whereas transdermal oestradiol/oral dydrogesterone and tibolone prevent the lean mass changes. Furthermore, oral oestradiol/dydrogesterone prevents the shift to a cen_tral, android fat distribution.</description><subject>Absorptiometry, Photon</subject><subject>Administration, Cutaneous</subject><subject>Administration, Oral</subject><subject>Biological and medical sciences</subject><subject>Body Composition - drug effects</subject><subject>Dydrogesterone - administration &amp; dosage</subject><subject>Dydrogesterone - therapeutic use</subject><subject>Estradiol - administration &amp; dosage</subject><subject>Estradiol - therapeutic use</subject><subject>Estrogen Replacement Therapy</subject><subject>Female</subject><subject>Genital system. Reproduction</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Norpregnenes - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><issn>0300-0664</issn><issn>1365-2265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><recordid>eNqNUcuO0zAUtRBoKAOfgGQhxC7Bj_glsWHK0EEaDRIPsbScxNa4JHGwE6b9Bn4ap626YMXG9r3nYd17AIAYlRhV_O22xJSzghDOSqyULBGqJC53j8DqDDwGK0QRKhDn1VPwLKUtQohJJC7AhRKYMsZX4M8H75yNdpi86aDvR9NMMDjYhOH30gxDbod4OOAUzZBaG_tc3ofYh8HCaMfONLbPZDjd22jG_YHq69AteBhgHdp9NuzHkPziCP0A83vKmjCaOWW3h5CL5-CJM12yL073Jfj-8frb-qa4_bz5tH5_WzQVE7hwitCaSaIqKRXBFUZEIMJbQTnnljpJW2JlUyFDOaJSCGdrRmlrkBRGOkQvwZuj7xjDr9mmSfc-NbbrzGDDnLTIIqoqnomv_iFuwxzzRpLGSuZNYi4ySR5JTQwpRev0GH1v4l5jpJew9FYvmeglE72EpQ9h6V2Wvjz5z3Vv27PwlE7GX59wkxrTubz-xqczjRDFJFvmeXekPfjO7v_7e72-vsuPLC-Ocp8muzvLTfyp83iC6R93G803X66k-Hqlb-hfce_AKA</recordid><startdate>199806</startdate><enddate>199806</enddate><creator>Hänggi, Willy</creator><creator>Lippuner, Kurt</creator><creator>Jaeger, Philippe</creator><creator>Birkhäuser, Martin H.</creator><creator>Horber, Fritz F.</creator><general>Blackwell Science Ltd, UK</general><general>Blackwell</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>199806</creationdate><title>Differential impact of conventional oral or transdermal hormone replacement therapy or tibolone on body composition in postmenopausal women</title><author>Hänggi, Willy ; Lippuner, Kurt ; Jaeger, Philippe ; Birkhäuser, Martin H. ; Horber, Fritz F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4571-f923b582948892141027026d73666e3f83d2e8c40a3603877feb533da087a8f03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Absorptiometry, Photon</topic><topic>Administration, Cutaneous</topic><topic>Administration, Oral</topic><topic>Biological and medical sciences</topic><topic>Body Composition - drug effects</topic><topic>Dydrogesterone - administration &amp; dosage</topic><topic>Dydrogesterone - therapeutic use</topic><topic>Estradiol - administration &amp; dosage</topic><topic>Estradiol - therapeutic use</topic><topic>Estrogen Replacement Therapy</topic><topic>Female</topic><topic>Genital system. Reproduction</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Norpregnenes - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hänggi, Willy</creatorcontrib><creatorcontrib>Lippuner, Kurt</creatorcontrib><creatorcontrib>Jaeger, Philippe</creatorcontrib><creatorcontrib>Birkhäuser, Martin H.</creatorcontrib><creatorcontrib>Horber, Fritz F.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical endocrinology (Oxford)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hänggi, Willy</au><au>Lippuner, Kurt</au><au>Jaeger, Philippe</au><au>Birkhäuser, Martin H.</au><au>Horber, Fritz F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Differential impact of conventional oral or transdermal hormone replacement therapy or tibolone on body composition in postmenopausal women</atitle><jtitle>Clinical endocrinology (Oxford)</jtitle><addtitle>Clinical Endocrinology</addtitle><date>1998-06</date><risdate>1998</risdate><volume>48</volume><issue>6</issue><spage>691</spage><epage>699</epage><pages>691-699</pages><issn>0300-0664</issn><eissn>1365-2265</eissn><coden>CLECAP</coden><abstract>OBJECTIVE To compare the effects on body composition and body weight of tibolone vs two different sequential oral or transdermal oestrogen‐progestogen hormone replacement therapies versus no therapy. PATIENTS AND METHODS One hundred postmenopausal women were assigned to a control group (n = 26), or randomized to 1) tibolone (TIB) 2.5 mg/day (n = 28), 2) oral oestradiol 2 mg/day (PO) plus sequential dydrogesterone 10 mg/day for 14 of 28 days per cycle (n = 26), or 3) transdermal oestradiol patch (TTS) releasing 50 μg/day plus oral sequential dydrogesterone 10 mg/day for 14 of 28 days per cycle (n = 20). Body composition was measured at the baseline and every 6 months for 2 years by DXA (Hologic QDR 1000 W). RESULTS Total body fat mass increased (P &lt; 0.05) in controls (+ 3.6 ± 1.5%) and in TTS treated (+ 4.7 ± 2.2%), but not in PO (−1.2 ± 2.4%) and TIB (−1.6 ± 2.2%) treated subjects. This increase in total fat mass in controls and TTS treated women was mostly due to an increase in fat mass of the trunk (P &lt; 0.05), but not legs. As a result, a redistribution of body fat to the trunk occurred in controls, TTS and TIB, but not in PO treated women (P &lt; 0.05). Total lean body mass decreased (P &lt; 0.02) in controls (−1.7 ± 0.7%) and PO (−1.4 ± 0.6%), but not in TTS (+ 0.3 ± 0.8%) and TIB (+ 0.4 ± 0.5%) treated subjects. CONCLUSIONS The menopause is associated with an increase in total body fat and a decline in lean body mass. Oral oestradiol/dydrogesterone and tibolone prevent total body fat changes, whereas transdermal oestradiol/oral dydrogesterone and tibolone prevent the lean mass changes. Furthermore, oral oestradiol/dydrogesterone prevents the shift to a cen_tral, android fat distribution.</abstract><cop>Oxford BSL</cop><pub>Blackwell Science Ltd, UK</pub><pmid>9713556</pmid><doi>10.1046/j.1365-2265.1998.00481.x</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0300-0664
ispartof Clinical endocrinology (Oxford), 1998-06, Vol.48 (6), p.691-699
issn 0300-0664
1365-2265
language eng
recordid cdi_proquest_miscellaneous_73873946
source Wiley-Blackwell Read & Publish Collection
subjects Absorptiometry, Photon
Administration, Cutaneous
Administration, Oral
Biological and medical sciences
Body Composition - drug effects
Dydrogesterone - administration & dosage
Dydrogesterone - therapeutic use
Estradiol - administration & dosage
Estradiol - therapeutic use
Estrogen Replacement Therapy
Female
Genital system. Reproduction
Humans
Medical sciences
Middle Aged
Norpregnenes - therapeutic use
Pharmacology. Drug treatments
title Differential impact of conventional oral or transdermal hormone replacement therapy or tibolone on body composition in postmenopausal women
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T02%3A00%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Differential%20impact%20of%20conventional%20oral%20or%20transdermal%20hormone%20replacement%20therapy%20or%20tibolone%20on%20body%20composition%20in%20postmenopausal%20women&rft.jtitle=Clinical%20endocrinology%20(Oxford)&rft.au=H%C3%A4nggi,%20Willy&rft.date=1998-06&rft.volume=48&rft.issue=6&rft.spage=691&rft.epage=699&rft.pages=691-699&rft.issn=0300-0664&rft.eissn=1365-2265&rft.coden=CLECAP&rft_id=info:doi/10.1046/j.1365-2265.1998.00481.x&rft_dat=%3Cproquest_cross%3E30738300%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4571-f923b582948892141027026d73666e3f83d2e8c40a3603877feb533da087a8f03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=198807167&rft_id=info:pmid/9713556&rfr_iscdi=true